Hepatitis C Virus (HCV) affects 6-11 million people in India. Chronic HCV infection is the leading cause for liver-related deaths worldwide. In India, HCV infection was estimated to be responsible for 59,000 deaths in the year 2015. Moreover, untreated HCV infection could also lead to substantial economic burden. However, the advent of directly acting antivirals (DAAs), is proving to be a game changer in HCV treatment. Directly acting antivirals target specific enzymes and the genetic material in HCV, hence stopping the spread of the infection.
Despite successful bans on the veterinary drug diclofenac in Nepal and parts of India, a decade-long undercover investigation reveals that toxic alternatives like flunixin and nimesulide are rapidly replacing it, posing a renewed existential threat to the region’s critically endangered vulture populations.
Mumbai/